Generic Wegovy has a new patent lawsuit, but the filing sets no U.S. launch date. Mylan is asking a court to clear one patent obstacle. That request is not a court victory or permission to sell a generic. Semaglutide is the medicine in Wegovy. For someone already prescribed it, the filing changes the legal story, not today's prescription choices.
What the generic Wegovy lawsuit asks
As of September 30, 2026, the day this article was written, Mylan's September 23 complaint challenges Novo Nordisk's U.S. Patent 12,551,536. The case is 1:26-cv-01192 in the federal district court in Delaware. Mylan, now part of Viatris, seeks a declaratory judgment: a court decision settling whether a patent can block its proposed product. The filed complaint asks for findings that its product would not infringe the patent, or that the patent is invalid.
The patent record shows a February 17, 2026 grant. Its first claim covers reducing body weight with semaglutide injected under the skin in an amount of 2–10 mg weekly. That range describes a patent claim, not a treatment schedule. The prescriber sets the actual dose.
Mylan says the patent should not stand in its way. The complaint gives Mylan's position; it does not establish that the court agrees.
What changes for someone prescribed semaglutide
The filing does not put a new generic on a pharmacy shelf. As of September 30, 2026, the day this article was written, FDA's September 14 patent-challenge list shows applications for generic Wegovy, with no first generic approval recorded.
Our generic semaglutide guide explains the broader U.S. picture. The Canada guide covers the separate question of Canadian products and cross-border access. A Delaware patent case does not turn a Canadian authorization into U.S. permission to market a medicine.
Through Promise, semaglutide is dispensed as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. A licensed provider may still prescribe a compounded formulation; that decision is between you and your doctor.
That prescription route is separate from Mylan's proposed generic. The lawsuit does not change a patient's dose, pharmacy label, or follow-up plan.
Why 45 days is not a launch countdown
Paragraph IV is a generic applicant's formal claim that a listed patent is invalid, unenforceable, or would not be infringed. FDA's explanation of the process, current September 21, 2026, describes notice to the patent owner and brand company.
A qualifying lawsuit filed within 45 days of receiving that notice generally triggers a 30-month stay: a delay in when FDA can make approval effective. The deadline runs from receipt, not mailing.
Mylan's complaint says it sent notice June 17. The Novo entities received it June 18 and 19, and neither sued within 45 days. That missed window does not cancel a patent.
There is another detail: FDA lists this patent's submission date as March 2, 2026, after Mylan's generic application. Under the federal rule, a patent listed after the original application does not generate another automatic 30-month stay. Other patent disputes and FDA's review remain separate questions.
Wegovy patent expiration is more than one date
FDA's Orange Book record, its list of drug patents and related protections, contains several patents for the 2.4 mg Wegovy pen. Three entries show why one date cannot settle availability:
| Listed patent | Listed expiration | What the date tells us |
|---|---|---|
| 8,129,343 | December 5, 2031 | One patent's term ends here |
| 12,551,536 | October 10, 2038 | The patent challenged in the new complaint |
| 11,318,191 | February 17, 2041 | Another listed patent extends beyond both |
These are patent dates, not promised launch dates. A court can find a patent invalid or find that a particular product does not infringe it. A settlement can also resolve a dispute.
An earlier decision illustrates the limits. On July 22, 2025, the court ruled for Mylan on Patent 9,764,003. It found no infringement based on Mylan's proposed label and that patent's claims. It did not invalidate every Wegovy patent or authorize a generic launch.
Compounded semaglutide is a separate prescription
Compounding means preparing a medicine for a particular prescription. It does not turn a preparation into generic Wegovy. FDA's telehealth guidance, current June 15, 2026, says compounded drugs do not undergo its review for safety, effectiveness, or quality before marketing. Our compounded semaglutide guide explains that distinction.
What a seller's label cannot tell us
The label matters here. A 2024 study in JAMA Network Open, Safety and Risk Assessment of No-Prescription Online Semaglutide Purchases, received products from only three of six selected sellers. Testing found 29–39% more semaglutide than the received products' labels claimed. This small sample concerned sellers operating without prescriptions; it does not describe licensed pharmacies generally.
A prescribed route provides a named clinician, an identifiable licensed U.S. pharmacy, and a care team for follow-up. Pharmacy accountability includes traceable lots, a label stating the contents and concentration, and a contact for reporting problems. A website calling its vial “generic” supplies none of that evidence by itself.
A future generic needs evidence about the finished product
A generic application must establish that the finished medicine meets FDA's requirements. FDA describes bioequivalence as comparing how much medicine reaches the bloodstream and how quickly. Sharing an ingredient name is not enough.
As of September 30, 2026, the day this article was written, FDA published revised draft testing guidance on July 28, including Wegovy and Ozempic. Its September 23–24 workshop listing also addressed testing and injection-device quality. Guidance and workshops describe development work; neither authorizes a particular generic.
A July 16, 2026 study in the Journal of Clinical and Translational Research compared Dr. Reddy's semaglutide injection with Ozempic. Its analysis included 74 healthy adults after one 0.5 mg dose. The products met the study's criteria for comparable blood exposure. Dr. Reddy's funded the study, and its authors were company employees.
Those results concern that tested product. They do not establish equivalence for Mylan's proposed Wegovy product or Promise's compounded preparation.
Tirzepatide is a different medicine
Tirzepatide is not a generic version of Wegovy. Semaglutide acts on GLP-1, a gut-hormone signal involved in fullness and blood-sugar regulation. Tirzepatide acts on GLP-1 and GIP, a second gut-hormone signal. Our tirzepatide and semaglutide comparison explains the evidence behind that difference.
Promise's tirzepatide is also a compounded prescription. Choosing between medicines involves medical history, prior response, and tolerability, meaning how well someone handles side effects. A patent headline does not decide that choice.
What to watch next
The useful milestones are court decisions, any settlement that resolves the disputed patents, and a final decision on the finished generic application. Each answers a different question: whether patents block a product, whether FDA's requirements are met, and whether the manufacturer can supply it.
Any new order needs to be read for its scope. A ruling about one patent or one proposed pen does not automatically cover other patents, strengths, or tablets. Likewise, a manufacturer's announcement is not the same document as a final regulatory decision. The product and application number need to match.
The question “when will Wegovy go generic?” cannot be answered by adding 45 days to a notice date. The listed patent dates are public; the outcome of this litigation remains unsettled.
At Promise, a licensed provider reviews every request, and not everyone qualifies. The current prescription discussion starts with medical eligibility and the exact preparation being offered.
